Heat Biologics Presents Topline HS-110/Nivolumab Combination Lung Cancer Results
Reports Positive Data on Primary Endpoint with Positive Safety Data Overall Survival Compares Favorably with Single-Agent Nivolumab Management to host a call on Thursday, December 8th, at 8:30 a.m. ET DURHAM, N.C., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Heat …